ビス(4-アミノフェニル) スルホン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H302：飲み込むと有害

  H370：臓器の障害

  H373：長期にわたる、または反復暴露により臓器の障 害のおそれ

  H411：長期的影響により水生生物に毒性

• 注意書き

  P260：粉じん/煙/ガス/ミスト/蒸気/スプレーを吸入しないこ と。

  P264：取扱い後は皮膚をよく洗うこと。

  P264：取扱い後は手や顔をよく洗うこと。

  P270：この製品を使用する時に、飲食または喫煙をしないこ と。

  P273：環境への放出を避けること。

  P301+P312：飲み込んだ場合：気分が悪い時は医師に連絡する こと。

ビス(4-アミノフェニル) スルホン 価格

MSDS Information

• Dapsonum

ビス(4-アミノフェニル) スルホン 化学特性,用途語,生産方法

• 外観

  白色～うすい黄色粉末～結晶

• 用途

  エポシキ樹脂硬化剤,ポリイミド原料,耐熱性電気絶縁物,接着剤原料、 皮膚炎、ハンセン病治療薬

• 効能

  ハンセン病治療薬

• 商品名

  プロトゲン (田辺三菱製薬); レクチゾール (田辺三菱製薬)

• 化学的特性

  Off -White Crystalline Solid

• 使用

  4,4'-diaminodiphenylsulfone be used for preparation polyimide and epoxy resin material.

• 定義

  ChEBI: A sulfone that is diphenylsulfone in which the hydrogen atom at the 4 position of each of the phenyl groups is substituted by an amino group. It is active against a wide range of bacteria, but is mainly employed for its actions against Mycobacteriu leprae, being used as part of multidrug regimens in the treatment of all forms of leprosy.

• 適応症

  Although dapsone (Avlosulfon) is most often used as an antimicrobial agent, it has important antiinflammatory properties in many noninfectious skin diseases. The mechanism of action of dapsone in skin disease is not clear.Most of the cutaneous diseases for which it is effective manifest inflammation and are characterized by an infiltration of neutrophils; the drug’s antiinflammatory effect may arise from its inhibition of intracellular neutrophil reactions mediated by myeloperoxidase and hydrogen peroxide or from its scavenging of reactive oxygen species, which inhibits inflammation.

• 抗菌性

  Dapsone is active against many bacteria and some protozoa. Fully susceptible strains of M. leprae are inhibited by a little as 0.003 mg/L. It is predominantly bacteristatic. Resistance is associated with mutations in the folP1 gene involved in the synthesis of para-aminobenzoic acid.

• 獲得抵抗性

  Resistance to high levels is acquired by several sequential mutations. As a result of prolonged use of dapsone monotherapy, acquired resistance emerged in patients with multibacillary leprosy in many countries. Initial resistance also occurs in patients with both paucibacillary and multibacillary leprosy. Thus, leprosy should always be treated with multidrug regimens. Resistance of M. leprae to dapsone (and other anti-leprosy drugs) may now be determined by use of DNA microarrays.

• 一般的な説明

  Odorless white or creamy white crystalline powder. Slightly bitter taste.

• 空気と水の反応

  Sensitive to oxidation and light. Insoluble in water.

• 反応プロフィール

  4,4'-Diaminodiphenylsulfone can neutralize acids in exothermic reactions to form salts plus water. May be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen is generated in combination with strong reducing agents, such as hydrides. Incompatible with strong oxidizing agents. Also incompatible with epoxy resins under uncontrolled conditions .

• 火災危険

  4,4'-Diaminodiphenylsulfone is probably combustible.

• 応用例（製薬）

  The most effective of a number of sulfonamide derivatives to be tested against leprosy. The dry powder is very stable. It is only slightly soluble in water.

• 薬物動態学

  Oral absorption: >90%
  C_max 100 mg oral: c. 2 mg/L after 3–6 h
  Plasma half-life: 10–50 h
  Plasma protein binding: c. 50%
  It is slowly but almost completely absorbed from the intestine and widely distributed in the tissues, but selectively retained in skin, muscle, kidneys and liver. It is metabolized by N-oxidation and also by acetylation, which is subject to the same genetic polymorphism as isoniazid. The elimination half-life is consequently very variable, but on standard therapy the trough levels are always well in excess of inhibitory concentrations. It is mostly excreted in the urine: in the unchanged form (20%), as N-oxidation products (30%) and as a range of other metabolites.

• 臨床応用

  Leprosy (multidrug regimens)
  Prophylaxis of malaria, treatment of chloroquine-resistant malaria (in combination with pyrimethamine)
  Prophylaxis of toxoplasmosis (in combination with pyrimethamine)
  Prophylaxis (monotherapy) and treatment (in combination with trimethoprim) of Pneumocystis jirovecii pneumonia
  Dermatitis herpetiformis and related skin disorders

• 副作用

  Although usually well tolerated at standard doses, gastrointestinal upsets, anorexia, headaches, dizziness and insomnia may occur. Less frequent reactions include skin rashes, exfoliative dermatitis, photosensitivity, peripheral neuropathy (usually in non-leprosy patients), tinnitus, blurred vision, psychoses, hepatitis, nephrotic syndrome, systemic lupus erythematosus and generalized lymphadenopathy.
  The term ‘dapsone syndrome’ is applied to a skin rash and fever occurring 2–8 weeks after starting therapy and sometimes accompanied by lymphadenopathy, hepatomegaly, jaundice and/or mononucleosis.
  Blood disorders include anemia, methemoglobinemia, sulfhemoglobinemia, hemolysis (notably in patients with glucose- 6-phosphate dehydrogenase deficiency), mononucleosis, leukopenia and, rarely, agranulocytosis. Severe anemia should be treated before patients receive dapsone.
  The incidence of adverse reactions declined in the 1960s but reappeared around 1982 when multidrug therapy was introduced, and may represent an unexplained interaction with rifampicin.

• 安全性プロファイル

  Poison by ingestion, intraperitoneal, and subcutaneous routes. Human systemic effects by ingestion: agranulocytosis, change in tubules and other kidney changes, cyanosis, effect on joints, hemolysis with or without anemia, jaundice, methemoglobinemiacarboxyhemoglobinemia, retinal changes, somnolence. Experimental reproductive effects. Can cause hepatitis, dermatitis, and neuritis. Questionable carcinogen with experimental carcinogenic and neoplastigenic data. Human mutation data reported. Used in leprosy treatment and veterinary medicine. When heated to decomposition it emits very toxic fumes of NOx and SOx. See also SULFONATES.

ビス(4-アミノフェニル) スルホン 上流と下流の製品情報

ビス(4-アミノフェニル) スルホン 生産企業

Global(716)Suppliers

ビス(4-アミノフェニル) スルホン スペクトルデータ(¹HNMR、¹³CNMR、IR1、IR2、MS、Raman)

80-08-0, ビス(4-アミノフェニル) スルホン キーワード